Ratings Progyny, Inc.

Equities

PGNY

US74340E1038

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
27.53 ^USD	-15.29%		-13.21%	-25.95%

May. 10	Top Midday Decliners	MT
May. 10	Sector Update: Health Care Stocks Advance Friday Afternoon	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 63% by 2026.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.13 times its estimated earnings per share for the ongoing year.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
PROGYNY, INC.	-25.95%	2.65B	C+
ELEVANCE HEALTH, INC.	+14.34%	125B	A-
CIGNA	+16.34%	98.97B	B-
CENTENE CORPORATION	+4.82%	41.51B	B-
HUMANA INC.	-26.70%	40.44B	A-
MOLINA HEALTHCARE, INC.	-1.86%	20.78B	B-
ALIGNMENT HEALTHCARE, INC.	-20.67%	1.31B	B-
CLOVER HEALTH INVESTMENTS, CORP.	-13.87%	407M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes